Biosimilars

Sanofi's latest FDA nod for Tzield isn't just a new drug approval; it's a strategic shift from symptom management to disease modification in Type 1 Diabetes.

MBX Biosciences' new one-year data for canvuparatide isn't just a clinical win; it's a calculated move to dominate a billion-dollar market left vacant.

A new FDA-designated device aims to filter a deadly protein from the blood of sepsis patients. Can this novel approach finally conquer a global health crisis?

A $4M grant for a Parkinson's drug isn't just charity; it's a strategic bet on a new era of medicine, where philanthropy acts as the catalyst for the next big cure.

At EHA 2026, Parexel isn't just presenting data; it's unveiling a bold new strategy to fix a broken system and accelerate life-saving blood cancer drugs.

Organon's FDA nod for TOFIDENCE in critical care isn't just a clinical win. It's a calculated move to capture market share and challenge high-cost biologics.

Sanofi's promising nerve disease drug fails in late-stage trials, leaving vulnerable patients in limbo and highlighting the brutal realities of medical innovation.

Takeda seeks FDA approval for its gut-focused drug ENTYVIO in children, a major step toward a new era of treatment for the rising tide of pediatric IBD.

A novel TYK2 inhibitor that can enter the central nervous system has begun human trials, signaling a new frontier for treating diseases like MS and lupus.

New long-term data for masitinib shows a near doubling of 5-year survival for ALS patients, with many maintaining quality of life. Is this the turning point?

With a novel 'gastric bypass in a pill' and a new CFO known for orchestrating lucrative exits, Syntis Bio is gearing up for a high-stakes battle in the booming obesity drug market.

A $20M round for CELYSTRA Pharma isn't just a launch; it's a strategic maneuver to solve Canada's rare disease gap and redefine Québec's role in the market.

New research from Baycrest unmasks paratonia, an involuntary condition often mistaken as defiance, signaling a seismic shift in dementia care and treatment.

As GLP-1 drugs dominate, a UK biotech reveals a new drug that targets mitochondria, promising superior fat loss while preserving precious muscle mass.

With expanded coverage for 52 million Americans, Tonix Pharmaceuticals' TONMYA® is not just a drug launch; it's a market disruption for chronic pain.

Zealand Pharma's petrelintide shows double-digit weight loss with remarkably few side effects, positioning it to challenge GLP-1 giants in the $100B market.

DBV Technologies heads to a key investor conference with its VIASKIN patch for peanut allergies. Can its science and strategy convince Wall Street?

As Royalty Pharma prepares for a key investor conference, we explore the powerful, low-profile business model that funds blockbuster drugs and shapes innovation.

A pharma revolution is brewing for Generalized Anxiety Disorder. As prevalence soars, novel therapies targeting new neural pathways promise to upend the market.

Teva's new Eylea biosimilar hits Europe, a key move in its 'Pivot to Growth' strategy that promises to shake up the lucrative ophthalmology market.